Chilton Lectures

Arthur L. Chilton and the A.L. Chilton Foundation have been instrumental to the success of the Department of Biochemistry at UT Southwestern Medical Center.

Mr. Chilton was the founder of Sky Broadcasting System, with radio stations broadcasting from Texas, Louisiana, and Arkansas. Mr. Chilton also was an active and very generous philanthropist, creating the Chilton Foundation in 1945 to support medical research, youth organizations, and other charities.\

He began supporting UT Southwestern biochemistry students in the 1950s because of an interest in lipid metabolism and research related to obesity. That grew into a sustained and long-term commitment to support the Department of Biochemistry.

Mr. Chilton died in 1973, but through his close friend, the late T. Andrew Bell, and subsequently his widow, Mar Nell, and daughters, Bonnie Harding and Pattie Brown, his legacy as a forward-thinking benefactor continues at UT Southwestern Medical Center.

2018 Chilton Lecture

Title: “Chemical Biology-based Approach to Understanding and Overcoming Cancer Therapy Resistance”

Time/Date: 4 p.m. April 18, 2018

Location: Excellence in Education Foundation Auditorium
Simmons Biomedical Research Building

Stuart Schreiber, Ph.D.
Stuart L. Schreiber, Ph.D.

About Dr. Schreiber

Stuart Schreiber has been a founding core member of the Broad Institute since 2003. He was the founding director in 1997 of Harvard’s Institute of Chemistry and Cell Biology, which provided the origins of the Broad Institute’s Chemical Biology Program, now part of the Chemical Biology and Therapeutic Sciences (CBTS) Program.

Schreiber is a world leader in chemical biology, using small molecules as probes in uncovering biological functions. He has provided some of the most significant small-molecule-based advances, including small-molecule probes of extremely difficult targets and processes (e.g., transcription factors, oncogenes, protein/protein interactions, transdifferentiation of cells) that are at the root of human disease.

His development of diversity-oriented synthesis, and integration of human biology and chemistry to guide the development of safe and effective therapeutics, among others, have dramatically advanced chemical biology and contributed to its becoming a vibrant area of life science research. Numerous new drugs for various indications (organ transplantation, dendritic cell vaccination, leukemia, multiple myeloma, and solid tumors, including carcinomas and sarcomas) have been approved and are being developed in which therapeutic effects are the direct consequence of proteins and/or cellular control mechanisms revealed by Schreiber’s research.

Schreiber is the Morris Loeb Professor in the Department of Chemistry and Chemical Biology at Harvard University and a Howard Hughes Medical Institute investigator. He is an elected member of the National Academy of Sciences and the American Academy of Arts and Sciences. He is the recipient of numerous awards, including the Tetrahedron Prize for Creativity in Organic Chemistry, Charles Butcher Award in Genomics and Biotechnology, the Association of American Cancer Institutes Distinguished Scientist Award, the Award for Outstanding Achievement in Chemistry in Cancer Research from the American Association for Cancer Research, the Arthur Cope Award from the American Chemical Society, and most recently the Wolf Prize in Chemistry.

Schreiber was a professor at Yale University from 1981 to 1988, and became a member of Harvard’s Department of Chemistry and Chemical Biology in 1988.

He received his B.A. in chemistry from the University of Virginia and his Ph.D. in organic chemistry from Harvard University.